Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...

We recently published a list of 10 Worst Performing Large Cap Stocks to Buy According to Analysts. In this article, we are ...

Regeneron Pharmaceuticals has built its success on a foundation of innovative drug development, with key products including Eylea for eye diseases and Dupixent for various inflammatory conditions.

Lilly said patients must refill their prescriptions of the two higher-dose vials within 45 days of their first fill to get the same pricing, and would otherwise have to pay as much as $699 for ...

Lilly Offers Weight-Loss Drugs in Vials at a Discount to Fight Competition By Patrick Wingrove and Sriparna Roy (Reuters) -Eli Lilly said on Tuesday it cut the price for vials of its weight-loss ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A bunch of people I know (including me) have gotten sick ...

Shares of the Indianapolis-based drugmaker rose 2.3% to $902.42. The launch of Lilly's vials expands options for patients who choose to pay cash through the drugmaker's direct-to-consumer website ...

FYB203 (aflibercept) approved in the UK for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases UK market authorization follows successful ...

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands ...